Adolor has plunked down $2 million upfront and committed to pay $70 million more in milestones for Eli Lilly's OpRA III, a clinical stage product being developed for opioid bowel dysfunction. Adolor says it will soon launch a new trial for the drug, which will be developed alongside ADL7445 as part of its OBD Program. From now on, OpRA III will be identified as ADL5945.
"OpRA III has a unique profile with the potential to address the gastrointestinal disorders associated with the use of opioid analgesics," said Michael R. Dougherty, president and CEO of Adolor. "Adolor has a wealth of experience in this therapeutic area and the addition of OpRA III to our OBD portfolio provides us with another clinical-stage compound with which we can potentially address a large and underserved market."
Lilly has completed both a Phase I single, escalating dose placebo-controlled safety study and a Phase I multiple, escalating dose placebo-controlled safety study in healthy volunteers for OpRA III.
- check out the release for more info